Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine: Feature

Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'who...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today Vol. 20; no. 12; pp. 1429 - 1432
Main Authors Thomas, David M, Fox, Stephen, Lorgelly, Paula K, Ashley, David, Richardson, Gary, Lipton, Lara, Parisot, John P, Lucas, Mark, McNeil, John
Format Journal Article
LanguageEnglish
Published 01.12.2015
Online AccessGet full text

Cover

More Information
Summary:Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:1359-6446
DOI:10.1016/j.drudis.2015.10.009